HOXA9 is a common driver of leukemia, one of the strongest predictors of survival in AML patients, and a transcriptional addiction in KMT2Ar AML (Andreeff et al. 2008; Faber et al. 2009; Dang 2012; Collins and Hess 2016). Here, HOXA9 is linked to leukemia.